Kyu-Youn Hwang serves as the CEO at CTBIO, a startup based in Korea. He earned his PhD in an interdisciplinary bioengineering program at Seoul National University in 2013. Before joining CTBIO in 2022, he spent 17 years (2002-2019) at Samsung Electronics in Korea. During his tenure, he was involved in developing in-vitro diagnostics (IVD) platforms, such as integrated PCR and clinical chemistry platforms (PT10), as well as healthcare and environmental sensors for Galaxy mobile phones. In 2019, Dr. Hwang moved to Precision Biosensor in Korea, where he led the assay development team for immuno- and clinical chemistry platforms (Exdia). As a managing director, he oversaw the entire product development lifecycle, including R&D, mass production, regulatory approvals, academic responses, and ensuring customer satisfaction. Dr. Hwang played a key role as an R&D member in the technology special listing of Precision Biosensor on the Korea KOSDAQ stock market in 2020. He possesses extensive experience and expertise in various point-of-care-testing (POCT) products, encompassing molecular diagnostics, immuno-diagnostics, and clinical chemistry. He has (co)authored over 20 technical publications, including presentations, and holds more than 50 patents across the US, Korea, and the EU.